BSE · 524711
Vista Pharmaceuticals Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹11 Cr with net profit ₹-5 Cr — a -44.21% net margin, versus -42.48% the period before.
Shareholding
As of 2026-06-30
- Promoter21.19%
- Public78.79%
- DII0.02%
14,154 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.01× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Formulations · ranked #32 of 50 by market cap · medians across 41 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Torrent Pharmaceuticals Limited | ₹1,85,543 Cr | 84.66 | 22.06 | 25.49% | 15.55% |
| Ajanta Pharma Limited | ₹42,371 Cr | 158.85 | 9.39 | 23.33% | 19.37% |
| Gland Pharma Limited | ₹41,979 Cr | 114.32 | 4.05 | 9.92% | 15.98% |
| Rubicon Research Limited | ₹25,225 Cr | 327.16 | 19.61 | 19.14% | 14.07% |
| Caplin Point Laboratories Ltd. | ₹19,866 Cr | 116.78 | 5.54 | 17.88% | 29.32% |
| Eris Lifesciences Limited | ₹19,790 Cr | 69.33 | 5.07 | 15.87% | 19.89% |
| Shilpa Medicare Ltd. | ₹11,832 Cr | 109.79 | 4.57 | 9.39% | 15.81% |
| Marksans Pharma Limited | ₹11,766 Cr | 79.4 | 3.89 | 13.82% | 14.16% |
| Senores Pharmaceuticals Limited | ₹6,092 Cr | 166.18 | 6.52 | 12.36% | 18.32% |
| Bliss GVS Pharma Ltd. | ₹4,875 Cr | 142.76 | 4.08 | 8.95% | 11.15% |
| Vista Pharmaceuticals Ltd.(this company) | ₹44 Cr | — | 1.21 | -33.1% | -223.33% |
AI analysis
AI-generated · google/gemini-2.5-flashVista Pharmaceuticals Ltd. has a market capitalization of Rs 44 Cr. The company reported revenue of Rs 10.52 Cr and a profit margin of -223.33%. The book value per share stands at Rs 5.92. Return on equity (ROE) is -33.1% and return on capital employed (ROCE) is -32.4164%. The debt-to-equity ratio is 0.18. The 52-week high for the share price was Rs 11.45 and the 52-week low was Rs 5.71.
Positives
- +The debt-to-equity ratio of 0.18 is relatively low.
Negatives
- −The company has posted a negative profit margin of -223.33%.
- −Return on equity (ROE) is negative at -33.1%.
- −Return on capital employed (ROCE) is negative at -32.4164%.
- −The company has reported negative EPS for the last five annual periods, with -0.79 in March 2025.
- −Promoter shareholding is 21.1856%, with public shareholders holding a majority of 78.7911% as of March 31, 2026.
Financial Performance
Vista Pharmaceuticals Ltd. reported revenue of Rs 10.52 Cr. The company's net profit was -4.6487 Cr for March 2025. Over the past five years, annual revenue has fluctuated, with Rs 1.46 Cr in March 2021, Rs 0.56 Cr in March 2022, Rs 1.40 Cr in March 2023, Rs 10.62 Cr in March 2024, and Rs 10.52 Cr in March 2025. The company has consistently reported negative net profits over this period.
Profitability & Returns
The company's profitability metrics indicate challenges, with a profit margin of -223.33%. Annual EPS has been negative across the last five reported periods, ranging from -0.24 in March 2022 to -0.9 in March 2023. Return on equity (ROE) stands at -33.1%, and return on capital employed (ROCE) is -32.4164%, both indicating that the company is not generating positive returns from its equity or capital.
Balance Sheet
Vista Pharmaceuticals Ltd. has a book value per share of Rs 5.92. The debt-to-equity ratio is 0.18, suggesting a low reliance on debt for financing. Over the last five annual periods, EBITDA has consistently been negative, with -4.3258 Cr in March 2025. The company has a market capitalization of Rs 44 Cr.
Ownership & Pledges
Public shareholding is 78.7911%. There is no FII holding reported. No promoter shares are reported as pledged. The total number of shareholders is 14,154 as of March 31, 2026.
Data as of — price: 2026-07-29 · financials: Mar 25 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.
Back to Vista Pharmaceuticals Ltd.share price & fundamentals